Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia

by D. A. Lebedev, A. Yu. Babenko
Published 2018-09-01

Construction of validation modules based on reference functional models in a standalone verification of communication subsystem

by D. A. Lebedev, I. A. Stotland
Published 2018-10-01

Evaluation of factors influencing adherence to treatment with sodium-glucose cotransporter type 2 inhibitor

by D. A. Lebedev, A. A. Mosikian, A. Yu. Babenko
Published 2020-10-01

LONG-TERM RESULTS OF ORGANOSAFE OPERATION IN OBSTRUCTIVE URETEROHYDRONEPHROSIS OF TERMINAL STAGE

by I. B. Osipov, D. A. Lebedev, A. A. Fedotkina
Published 2018-01-01

Kidney triplication with ectopic ureterocele: a case report

by I. B. Osipov, D. A. Lebedev, M. V. Lifanova
Published 2020-05-01

Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis

by D. A. Lebedev, E. A. Lyasnikova, E. Yu Vasilyeva, A. Yu Babenko, E. V. Shlyakhto
Published 2020-01-01

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELL...

by D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko
Published 2017-11-01

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes

by D. A. Lebedev, E. A. Lyasnikova, A. A. Vasilyeva, E. Yu. Vasilyeva, A. Yu. Babenko, E. V. Shlyakhto
Published 2020-11-01

NEW PERSPECTIVE FOR THE USE OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN DIABETES MELLITUS

by V. K. Bayrasheva, I. Yu. Pchelin, A. N. Arefjeva, P. A. Andoskin, V. N. Vasilkova, D. A. Lebedev, S. G. Chefu
Published 2017-05-01